Follow on Google News News By Tag * Inflammatory Bowel Disease * Crohn S Disease * Ulcerative Colitis * Biological Drugs * Intestinal Medicines * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Medicines for Crohn’s disease and ulcerative colitis to reach $10.2bn overall in 2018By: Visiongain That investigation predicts the IBD treatment market will grow in revenues owing to the increasing use of biological (http://www.visiongain.com/ Sandra Wenas, a pharmaceutical industry analyst in visiongain, said: “The world IBD drug market will show strong sales growth over the next five years from 2014. The increased use of biologics will be the main sales driver in that market. Cost containment may form a restraint, though. Still, as more doctors advocate the top-down approach and more studies justify the cost effectiveness of monoclonal antibodies, biologic therapies are expected to gain higher usage, to claim 67% of that treatment market’s revenues by 2025. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries. The cost advantage of aminosalicylates will be more pronounced in those regions.” That study also finds that developed world markets make up the majority of the overall world IBD market, but emerging national markets, particularly India and China, will also show strong revenue growth from 2014. That overall market holds high commercial potential and strong research and development to yield future therapies, also expanding that industry and market. The new investigation shows revenue forecasts to 2025 at overall world market, submarket, product and national level. As well as predicting the overarching world market, that work forecasts its five main components: Aminosalicylates Antibiotics Corticosteroids Biologic therapies (biological drugs) Immunomodulators. That report also predicts revenues of 17 leading inflammatory bowel disease treatments to 2025, including Remicade, Humira, Asacol and the newly approved treatments Uceris, Simponi and Entyvio. The analysis includes trends and forecasted revenues for national markets. There it studies the US, Japan, Germany, France, the UK, Spain, Italy, Brazil, Russia, India and China. That investigation also assesses products in development, showing R&D for treating those gastrointestinal disorders. The work also gives interviews with two authorities. Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Those studies cover medical devices, diagnostics and pharmaceuticals. For further information about this report please visit https://www.visiongain.com/ Contact: Sara Peerun on sara.peerun@ Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail tosara.peerun@ About Visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. End
Account Phone Number Disclaimer Report Abuse
|
|